AbCellera Biologics

Short interest: 22.71% of float, squeeze risk: HIGH

6 PubMed publications found for AbCellera Biologics

A phase 2 randomized controlled trial using biologics to improve multi OIT outcomes (COMBINE): design, rationale, and methods.

Efficacy and safety of obeldesivir in low-risk, non-hospitalised patients with COVID-19 (OAKTREE): a phase 3, randomised, double-blind, placebo-controlled study.

Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical Severity-IVY Network, 26 Hospitals, 18 October 2023-9 March 2024.

Efficacy and Safety of Remdesivir in People With Impaired Kidney Function Hospitalized for COVID-19 Pneumonia: A Randomized Clinical Trial.

Association of Remdesivir Treatment With Mortality Among Hospitalized Adults With COVID-19 in the United States.

SW convergence: 59/100 (Neutral), 2 bullish / 1 bearish signals

SW convergence: 69/100 (Bullish Convergence), 3 bullish / 0 bearish signals

SW convergence: 69/100 (Bullish Convergence), 4 bullish / 1 bearish signals

SW convergence: 59/100 (Neutral), 3 bullish / 2 bearish signals

SW convergence: 64/100 (Bullish Convergence), 3 bullish / 1 bearish signals

SW convergence: 55/100 (Neutral), 3 bullish / 1 bearish signals

SW convergence: 50/100 (Neutral), 2 bullish / 1 bearish signals

SW convergence: 50/100 (Neutral), 1 bullish / 0 bearish signals

<article class="bts-verified-summary" data-ticker="ABCL">
<p>AbCellera Biologics (ABCL) is the lead sponsor of 2 active clinical trials listed on ClinicalTrials.gov<sup><a href="#fn-3">[3]</a></sup>, including 1 Phase 2<sup><a href="#fn-1">[1]</a></sup>, 2 Phase 1<sup><a href="#fn-2">[2]</a></sup>.</p>
<p>No Form 4 insider filings for ABCL were recorded at the SEC in the past 30 days<sup><a href="#fn-4">[4]</a></sup>.</p>
<section class="sources" data-nosnippet aria-label="Sources"><h3>Sources</h3><ol><li id="fn-1">ClinicalTrials.gov (2026-04-11) <a href="https://clinicaltrials.gov/search?term=AREA%5BLeadSponsorName%5D+%22AbCellera+Biologics%22&amp;aggFilters=status%3Arec%2Cact" rel="nofollow noopener noreferrer">↗</a></li>
<li id="fn-2">ClinicalTrials.gov (2026-04-11) <a href="https://clinicaltrials.gov/search?term=AREA%5BLeadSponsorName%5D+%22AbCellera+Biologics%22&amp;aggFilters=status%3Arec%2Cact" rel="nofollow noopener noreferrer">↗</a></li>
<li id="fn-3">ClinicalTrials.gov (2026-04-11) <a href="https://clinicaltrials.gov/search?term=AREA%5BLeadSponsorName%5D+%22AbCellera+Biologics%22&amp;aggFilters=status%3Arec%2Cact" rel="nofollow noopener noreferrer">↗</a></li>
<li id="fn-4">SEC EDGAR · 0001703057 (2026-04-11) <a href="https://efts.sec.gov/LATEST/search-index?q=%22ABCL%22&amp;forms=4&amp;dateRange=custom&amp;startdt=2026-03-12&amp;enddt=2026-04-11" rel="nofollow noopener noreferrer">↗</a></li></ol></section>
</article>

ClinicalTrials.gov

SEC EDGAR — 0001703057

AbCellera Biologics (ABCL) — BioTechSigns Verified Summary

AbCellera Biologics (ABCL) is the lead sponsor of 2 active clinical trials listed on ClinicalTrials.gov[3], including 1 Phase 2[1], 2 Phase 1[2].

No Form 4 insider filings for ABCL were recorded at the SEC in the past 30 days[4].

Sources:
[1] ClinicalTrials.gov. Source last updated 2026-04-11, retrieved 2026-04-11.
    https://clinicaltrials.gov/search?term=AREA%5BLeadSponsorName%5D+%22AbCellera+Biologics%22&aggFilters=status%3Arec%2Cact
[2] ClinicalTrials.gov. Source last updated 2026-04-11, retrieved 2026-04-11.
    https://clinicaltrials.gov/search?term=AREA%5BLeadSponsorName%5D+%22AbCellera+Biologics%22&aggFilters=status%3Arec%2Cact
[3] ClinicalTrials.gov. Source last updated 2026-04-11, retrieved 2026-04-11.
    https://clinicaltrials.gov/search?term=AREA%5BLeadSponsorName%5D+%22AbCellera+Biologics%22&aggFilters=status%3Arec%2Cact
[4] SEC EDGAR, 0001703057. Source last updated 2026-04-11, retrieved 2026-04-11.
    https://efts.sec.gov/LATEST/search-index?q=%22ABCL%22&forms=4&dateRange=custom&startdt=2026-03-12&enddt=2026-04-11

This study aims to assess the safety and tolerability of ABCL575 in healthy participants following single ascending dose (SAD), in comparison to a placebo

A First-in-Human Phase 1 Single-Ascending Dose Study of ABCL575 in Healthy Participants

The purpose of this study is to evaluate the effects of single and multiple doses of ABCL635 administered by subcutaneous (SC) injection to healthy men and to postmenopausal women with or without any vasomotor symptoms (VMS) or hot flashes, and to postmenopausal women with moderate-to-severe VMS associated with menopause. The safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) parameters of ABCL635 will be assessed in all study participants; the effects on frequency and severity of VMS will be assessed in postmenopausal women who experience moderate-to-severe symptoms.